Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial

Background: Bone marrow-derived early outgrowth cells (EOCs) secrete soluble factors that exert potent renoprotective effects, such that infusion of their conditioned medium recapitulates the affects of the cells themselves. Objectives: The objective of this study is to test whether the protective e...

Full description

Bibliographic Details
Main Authors: Darren A. Yuen, David M. Kepecs, Yanling Zhang, Suzanne Advani, Kerri Thai, Kim A. Connelly, Richard E. Gilbert
Format: Article
Language:English
Published: SAGE Publishing 2015-11-01
Series:Canadian Journal of Kidney Health and Disease
Online Access:https://doi.org/10.1186/s40697-015-0082-5
id doaj-e422f8b699cf4b118277fc8c5d1d3dd8
record_format Article
spelling doaj-e422f8b699cf4b118277fc8c5d1d3dd82020-11-25T03:29:20ZengSAGE PublishingCanadian Journal of Kidney Health and Disease2054-35812015-11-01210.1186/s40697-015-0082-5Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled TrialDarren A. Yuen0David M. Kepecs1Yanling Zhang2Suzanne Advani3Kerri Thai4Kim A. Connelly5Richard E. Gilbert6 Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario M5B 1T8, Canada Division of Endocrinology, Department of Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 209 Victoria Street, Room 508, Toronto, ON M5B 1T8, CanadaBackground: Bone marrow-derived early outgrowth cells (EOCs) secrete soluble factors that exert potent renoprotective effects, such that infusion of their conditioned medium recapitulates the affects of the cells themselves. Objectives: The objective of this study is to test whether the protective effect of conditioned medium infusion wanes with time and whether tachyphylaxis occurs with repeated administration. Design: This is a placebo-controlled animal study. Setting: The study was conducted at St. Michael's Hospital, Toronto, Ontario, Canada. Subjects: Fischer 344 (F344) rats were used in this study. Measurements: The following were measured: (1) urinary protein:creatinine ratio, (2) glomerular filtration rate, (3) systolic blood pressure, (4) body weight, (5) glomerular endothelial cell density, and (6) glomerular and tubulointerstitial type IV collagen deposition. Methods: Subtotally nephrectomized F344 rats, a model of progressive chronic kidney disease, were randomized 4 weeks post-surgery to receive thrice-weekly intravenous injections of concentrated EOC-conditioned medium (EOC CM) or unconditioned medium (UCM) over 2 weeks. Three animal groups were studied, according to whether they were administered conditioned medium: once (Initial Therapy Only group), twice (Repeat Therapy group), or not at all (No Therapy group). Results: Following initial therapy, EOC CM-treated animals excreted less urinary protein, a marker of renal injury, than their UCM-treated counterparts. At 10 weeks post-subtotal nephrectomy, however, mean urinary protein excretion in conditioned medium-treated animals was fourfold greater than at the completion of the initial treatment course. At this time point, conditioned medium-treated animals were randomized to receive a second course of either conditioned medium (Repeat Therapy group) or unconditioned medium (Initial Therapy Only group). At study end (14 weeks post-subtotal nephrectomy), Repeat Therapy animals demonstrated higher glomerular filtration rate, less proteinuria, preserved renal microvasculature, and diminished fibrosis when compared with the No Therapy group. Initial Therapy Only animals exhibited an intermediate effect. Limitations: Testing the effect of EOC-conditioned medium in a single model of chronic kidney disease (CKD) has limitations. Conclusions: These findings suggest that early outgrowth cell-derived factors, while renoprotective, have a limited duration of action. Repeated administration of these factors, however, is able to extend the duration of efficacy and attenuate the progression of experimental chronic kidney disease.https://doi.org/10.1186/s40697-015-0082-5
collection DOAJ
language English
format Article
sources DOAJ
author Darren A. Yuen
David M. Kepecs
Yanling Zhang
Suzanne Advani
Kerri Thai
Kim A. Connelly
Richard E. Gilbert
spellingShingle Darren A. Yuen
David M. Kepecs
Yanling Zhang
Suzanne Advani
Kerri Thai
Kim A. Connelly
Richard E. Gilbert
Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial
Canadian Journal of Kidney Health and Disease
author_facet Darren A. Yuen
David M. Kepecs
Yanling Zhang
Suzanne Advani
Kerri Thai
Kim A. Connelly
Richard E. Gilbert
author_sort Darren A. Yuen
title Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial
title_short Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial
title_full Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial
title_fullStr Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial
title_full_unstemmed Repeated Treatment with Bone Marrow Cell Secretory Products Maintains Long-Term Renoprotection in Experimental Chronic Kidney Disease: A Placebo-Controlled Trial
title_sort repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial
publisher SAGE Publishing
series Canadian Journal of Kidney Health and Disease
issn 2054-3581
publishDate 2015-11-01
description Background: Bone marrow-derived early outgrowth cells (EOCs) secrete soluble factors that exert potent renoprotective effects, such that infusion of their conditioned medium recapitulates the affects of the cells themselves. Objectives: The objective of this study is to test whether the protective effect of conditioned medium infusion wanes with time and whether tachyphylaxis occurs with repeated administration. Design: This is a placebo-controlled animal study. Setting: The study was conducted at St. Michael's Hospital, Toronto, Ontario, Canada. Subjects: Fischer 344 (F344) rats were used in this study. Measurements: The following were measured: (1) urinary protein:creatinine ratio, (2) glomerular filtration rate, (3) systolic blood pressure, (4) body weight, (5) glomerular endothelial cell density, and (6) glomerular and tubulointerstitial type IV collagen deposition. Methods: Subtotally nephrectomized F344 rats, a model of progressive chronic kidney disease, were randomized 4 weeks post-surgery to receive thrice-weekly intravenous injections of concentrated EOC-conditioned medium (EOC CM) or unconditioned medium (UCM) over 2 weeks. Three animal groups were studied, according to whether they were administered conditioned medium: once (Initial Therapy Only group), twice (Repeat Therapy group), or not at all (No Therapy group). Results: Following initial therapy, EOC CM-treated animals excreted less urinary protein, a marker of renal injury, than their UCM-treated counterparts. At 10 weeks post-subtotal nephrectomy, however, mean urinary protein excretion in conditioned medium-treated animals was fourfold greater than at the completion of the initial treatment course. At this time point, conditioned medium-treated animals were randomized to receive a second course of either conditioned medium (Repeat Therapy group) or unconditioned medium (Initial Therapy Only group). At study end (14 weeks post-subtotal nephrectomy), Repeat Therapy animals demonstrated higher glomerular filtration rate, less proteinuria, preserved renal microvasculature, and diminished fibrosis when compared with the No Therapy group. Initial Therapy Only animals exhibited an intermediate effect. Limitations: Testing the effect of EOC-conditioned medium in a single model of chronic kidney disease (CKD) has limitations. Conclusions: These findings suggest that early outgrowth cell-derived factors, while renoprotective, have a limited duration of action. Repeated administration of these factors, however, is able to extend the duration of efficacy and attenuate the progression of experimental chronic kidney disease.
url https://doi.org/10.1186/s40697-015-0082-5
work_keys_str_mv AT darrenayuen repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial
AT davidmkepecs repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial
AT yanlingzhang repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial
AT suzanneadvani repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial
AT kerrithai repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial
AT kimaconnelly repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial
AT richardegilbert repeatedtreatmentwithbonemarrowcellsecretoryproductsmaintainslongtermrenoprotectioninexperimentalchronickidneydiseaseaplacebocontrolledtrial
_version_ 1724579894687432704